Delcath Systems DCTH Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Product revenue by Product | |||||
| CHEMOSAT | $6.4M+30.5% | $4.9M+137% | $2.07M— | —— | |
| HEPZATO KIT | $78.84M+144% | $32.3M— | $0— | —— | |
| Number of orphan drug designations granted by FDA by Product | |||||
| HEPZATO KIT, Doxorubicin | 4— | —— | —— | —— | |
| HEPZATO KIT, Melphalan | 20— | —— | —— | —— | |
| HEPZATO KIT | 24— | —— | —— | —— | |
| Operating Lease, Payments by Geography | |||||
| Ireland | $46K+7.0% | $43K+30.3% | $33K-10.8% | $37K-74.8% | |
| U.S. | $144K+20.0% | $120K-49.6% | $238K-41.4% | $406K-2.6% | |
| Lessee, Operating Lease, Liability, to be Paid by Geography | |||||
| Ireland | $175K-47.9% | $336K-28.4% | $469K-28.0% | $651K+24.0% | |
| U.S. | $5.19M-10.0% | $5.77M+4,961% | $114K-88.2% | $964K-61.4% | |
| Lessee, Operating Lease, Liability, Undiscounted Excess Amount by Geography | |||||
| Ireland | $7K-70.8% | $24K-52.9% | $51K-44.6% | $92K— | |
| U.S. | $1.45M-17.7% | $1.76M+88,100% | $2K-92.9% | $28K-82.6% | |
| Weighted average discount rate - operating leases by Geography | |||||
| Ireland | 32%0.0pp | 32%0.0pp | 32%0.0pp | 32%0.0pp | |
| U.S. | 32%0.0pp | 32%0.0pp | 32%0.0pp | 32%0.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Delcath Systems break its business down?
- Delcath Systems (DCTH) reports product revenue by product across 2 parts — CHEMOSAT and HEPZATO KIT. Each is extracted from the segment footnotes and tracked over time.
- Where does Delcath Systems's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Delcath Systems's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
